免疫重建与系统性硬化症患者自体造血干细胞移植后良好临床反应相关
该研究对31例接受自体造血干细胞移植(AHSCT)的系统性硬化症(SSc)患者进行36个月随访,回顾性分为临床反应者25例与无反应者6例。移植后1年胸腺重建使免疫系统更新,Treg与Breg计数升高;无反应者Treg和Breg未升高且TCR库重叠高。
要点
- AHSCT后1年胸腺重建带来TCR多样性增高及Treg与近期胸腺 emigrant 正相关。
- AHSCT后6个月新生成初始B细胞增加,6和12个月Breg升高且白介素-10产生增多。
- 无反应者移植后Treg和Breg未升高,移植前后TCR库高度重叠。
核心结论
- 系统性硬化症患者AHSCT后临床改善与胸腺和骨髓协调重建所致新生成Treg和Breg计数增加相关。
研究设计与样本
- 对31例接受AHSCT的系统性硬化症患者进行移植后36个月同步临床与免疫学评估的回顾性研究,按临床反应分为反应者25例和无反应者6例。
主要发现
- 移植后1年评估时,全部移植患者胸腺重建致免疫系统更新,TCR多样性高于移植前,近期胸腺 emigrant 与Treg计数正相关,Treg上CTLA-4和GITR表达高于移植前。
- 移植后6个月起骨髓新生成初始B细胞输出增加,更新外周血B细胞群;移植后6和12个月Breg升高且白介素-10水平高于移植前。
- 无反应者移植后Treg和Breg计数未增加,移植前后TCR库高度重叠提示 underlying 疾病机制维持。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluate the immunological mechanisms associated with clinical outcomes after autologous hematopoietic stem cell transplantation (AHSCT), focusing on regulatory T- (Treg) and B- (Breg) cell immune reconstitution, 31 systemic sclerosis (SSc) patients underwent simultaneous clinical and immunological evaluations over 36-month posttransplantation follow-up. Patients were retrospectively grouped into responders (n = 25) and nonresponders (n = 6), according to clinical response after AHSCT. Thymic function and B-cell neogenesis were respectively assessed by quantification of DNA excision circles generated during T- and B-cell receptor rearrangements. At the 1-year post-AHSCT evaluation of the total set of transplanted SSc patients, thymic rebound led to renewal of the immune system, with higher T-cell receptor (TCR) diversity, positive correlation between recent thymic emigrant and Treg counts, and higher expression of CTLA-4 and GITR on Tregs, when compared with pretransplant levels. In parallel, increased bone marrow output of newly generated naive B-cells, starting at 6 months after AHSCT, renovated the B-cell populations in peripheral blood. At 6 and 12 months after AHSCT, Bregs increased and produced higher interleukin-10 levels than before transplant. When the nonresponder patients were evaluated separately, Treg and Breg counts did not increase after AHSCT, and high TCR repertoire overlap between pre- and posttransplant periods indicated maintenance of underlying disease mechanisms. These data suggest that clinical improvement of SSc patients is related to increased counts of newly generated Tregs and Bregs after AHSCT as a result of coordinated thymic and bone marrow rebound.
引用
- Arruda LCM, Malmegrim KCR, Lima-Júnior JR, et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Adv. 2018. PMID: 29365321. doi:10.1182/bloodadvances.2017011072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。